Bris­tol-My­ers, Scripps re­search team touts a new way to con­trol 3D ar­chi­tec­ture of ge­net­ic drugs

When­ev­er a pa­tient is giv­en one dose of an an­ti­sense drug — like the spinal mus­cu­lar at­ro­phy treat­ment Spin­raza — chances are they are ac­tu­al­ly re­ceiv­ing thou­sands …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER